Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 100.13B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 15.77 |
| Forward PE | 10.01 |
| Dividend | 3.92 (4.76%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 1,464,645 |
| Average Volume | 1,948,870 |
| Open | 82.53 |
| Previous Close | 82.29 |
| Day's Range | 81.66 - 82.75 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.40 |
| RSI | 47.76 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced toda...
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Sanofi's (SNY) Tzield Under Priority Review for Type 1 Diabetes
Sanofi's (SNY) Tzield Under Priority Review for Type 1 Diabetes
Sanofi’s Tzield accepted for FDA priority review in younger type 1 diabetes patients
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
FDA Accepts Sanofi's Tzield SBLA Priority Review To Expand Use In Children 1+ For Type 1 Diabetes
(RTTNews) - Sanofi (SNY, SAN.PA) announced that the U.S. Food and Drug Administration has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv)...
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1...
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1...
Witnessing An Insider Decision, George L Sing Exercises Options Valued At $2.32M At Regeneron Pharmaceuticals
In a new SEC filing on December 31, it was revealed that Sing, Board Member at Regeneron Pharmaceuticals (NASDAQ: REGN), executed a significant exercise of company stock options. What Happened: A For...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan
A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements bef...
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk
Sanofi acquires Dynavax for $2.2B, boosting its vaccine portfolio with HEPLISAV-B and a shingles candidate. Click for my latest analysis of SNY and DVAX stocks.
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why
Dynavax Technologies Corporation (NASDAQ: DVAX) shares are trending on Thursday. Check out the current price of DVAX stock here . Shares of the California-based biopharmaceutical company surged 38.19...
What Sanofi Is Getting Through The Acquisition Of Dynavax
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Sanofi (SNY) Faces FDA Rejection for Tolebrutinib in MS Treatment
Sanofi (SNY) Faces FDA Rejection for Tolebrutinib in MS Treatment
Sanofi multiple sclerosis therapy rejected by the FDA
Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple sclerosis drug tolebrutinib. Read more here.